Lowest Price Guaranteed From USD 4,499
Published
October 2019
Pages
427
View Count
19387
Example Insights
 |
 |
 |
 |
 |
 |
 |
 |
 |
Report Description
The global cell and advanced therapies supply chain management market is likely to be worth $159 million and this value is projected to reach $1,508 million by 2030, growing at an annualized rate of 25% in the given period. Advanced therapy medicinal products, such as cell and gene therapies, have revolutionized healthcare practices. The introduction of such treatment options has led to a paradigm shift in drug development, production and consumption. Moreover, such therapies have actually enabled healthcare providers to treat several difficult-to-treat clinical conditions. In the past two decades, more than 30 such therapy products have been approved; recent approvals include Zolgensma® (2019), RECELL® System (2018), AmnioFix® (2018), EpiFix® (2018), EpiBurn® (2018), Alofisel® (2018), LUXTURNA™ (2017), Yescarta® (2017), and Kymriah® (2017). Further, according to a report published by The Alliance for Regenerative Medicine in 2019, more than 1,000 clinical trials are being conducted across the globe by over 900 companies. In 2018, around USD 13 billion was invested in this domain, representing a 73% increase in capital investments in this domain, compared to the previous year. It is worth highlighting that, based on an assessment of the current pipeline of cell therapies and the historical clinical success of such products, it is likely that around 10-20 advanced therapies are approved by the US FDA each year, till 2025.
The commercial success of cell and advanced therapies is not only tied to whether they are capable of offering the desired therapeutic benefits, but also on whether the developers are able to effectively address all supply chain requirements. The advanced therapy medicinal products supply chain is relatively more complex compared to the conventional pharmaceutical supply chain. As a result, there are a number of risks, such as possible operational inefficiencies, capacity scheduling concerns, process delays leading to capital losses, and deliverable tracking-related issues, which need to be taken into consideration by therapy developers. These concerns are likely to escalate multi-fold when dynamic situations, such as the ongoing COVID-19 pandemic, significantly disrupt the overall supply chains. This has generated a need for bespoke technological solutions, which can be integrated into existing processes to enable the engaged stakeholders to oversee and manage the various aspects of the cell and advanced therapies supply chain, in compliance to global regulatory standards. Over the years, several innovative, software-enabled systems, offering supply chain orchestration and needle-to-needle traceability, have been developed. The market has also recently witnessed the establishment of numerous partnerships, most of which are agreements between therapy developers and software solutions providers. Further, given the growing demand for cost-effective personalized medicinal products, and a myriad of other benefits of implementing such software solutions, the niche market is poised to grow significantly in the foreseen future.
The ‘Cell and Advanced Therapies Supply Chain Management Market: Focus on Technological Solutions, 2019-2030’ report features an extensive study of the growing supply chain management software solutions market. The focus of this study is on software systems, including cell orchestration platforms (COP), enterprise manufacturing systems (EMS), inventory management systems (IMS), laboratory information management systems (LIMS), logistics management systems (LMS), patient management systems (PMS), quality management systems (QMS), tracking and tracing software (TTS), and other such platforms that are being used to improve / optimize various supply chain-related processes of cell and advanced therapies. Amongst other elements, the report features:
One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the supply chain management software solutions market. Based on multiple parameters, such as number of cell and advanced therapies under development, expected pricing, likely adoption rates, and potential cost saving opportunities from different software systems, we have developed informed estimates of the evolution of the market, over the period 2019-2030. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.
The opinions and insights presented in this study were influenced by discussions conducted with several stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the cell and advanced therapies supply chain solutions market in the mid to long term.
Chapter 3 is an introductory chapter that presents a general overview of the cell and advanced therapies domain, along with details on the various types of such products and the current therapy landscape. It features a detailed discussion on the cell and advanced therapies supply chain and key challenges related to different processes / stakeholders involved in this segment of the industry. The chapter also provides information on various software-enabled systems, highlighting their key advantages and associated challenges. Further, the chapter describes the key growth drivers and roadblocks related to the use of such solutions in the cell and advanced therapies supply chain, offering insights on the emergence of advanced, digital technologies in the domain, as well.
Chapter 4 includes information on more than 160 technological platforms that are currently being used for managing the critical intricacies within the cell and advanced therapies supply chain. It features detailed information on the different types of software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, TTS, and others), their key specifications and benefits (chain of identity and custody, compatibility and integration, data management and analytics, regulatory compliance, reliability and security, scalability, software-as-a-service, traceability, user-friendliness, workflow management, and others), affiliated modes of deployment (cloud and on-premises), scale of management (small enterprise, mid-size enterprise and large enterprise), end users (biobanks, cell therapy labs, hospitals, research institutes, commercial organizations, and others), applications (ordering and scheduling, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), regulatory certifications / accreditations (21 CFR Part 11, CLIA, FACT-JACIE, GAMP 5, GDPR, HIPAA, and others), and key support services offered (customization, installation / implementation, maintenance, training / technical support, upgradation, validation and testing, and others).
Chapter 5 features an insightful competitiveness analysis of the software solutions providers based on various parameters, such as number of software systems offered, affiliated modes of deployment, scale of management, end users, applications, regulatory certifications / accreditations, support services offered, and key platform specifications and benefits. In the chapter, stakeholder entities have been plotted on a 2X2 matrix, having a company’s Supplier Power (based on its employee base and years of experience in the industry) and Company Competitiveness as the two axes.
Chapter 6 includes elaborate profiles of companies that are currently offering core supply chain management software systems, such as EMS, IMS, LIMS, LMS, PMS, QMS, and TTS (shortlisted on the basis of company competitiveness analysis scores); each profile features an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
Chapter 7 presents a brief introduction to COPs, along with insights into their key functions and implementation strategies, while also considering their strategic position and connectivity with other adjacent systems within the entire cell and advanced therapies supply chain. Further, the chapter includes a brief discussion on the growing popularity of COP on the social media platform, Twitter, and presents a snapshot of how the public opinion about such technological solutions has evolved in the period 2014-2018. In addition, the chapter features detailed profiles of all the industry players that are currently offering COPs for supply chain management. For each of these companies, we have presented detailed profiles, featuring an overview of the company, its financial information (if available), and a detailed description of the platform(s). Each profile also includes a list of recent developments, highlighting key achievements, partnership activity and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
Chapter 8 provides information on funding instances and investments that have been made within the cell and advanced therapies supply chain management market. The chapter includes details on various types of investments (such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings) received by companies between 2014 and Q3 2019, highlighting the growing interest of the venture capital community and other strategic investors in this domain.
Chapter 9 features an elaborate discussion and analysis of partnerships / collaborations that have been established in the domain in the period between 2014 and Q3 2019. It includes a brief description of various types of partnership models (such as software licensing agreements, mergers and acquisitions, product development agreements, product integration agreements, distribution agreements, asset purchase agreements, and others) that have been employed by stakeholders within this domain. It also consists of a schematic representation showcasing the players that have established the maximum number of alliances in this industry. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.
Chapter 10 presents a detailed analysis of platform utilization use cases where the aforementioned software systems were leveraged by various stakeholders in the domain, in the period between 2014 and Q3 2019. It includes a brief discussion on the ways in which companies have implemented such software solutions to improve / optimize various supply chain-related processes of cell and advanced therapies.
Chapter 11 provides a qualitative assessment of the current and long-term needs of different stakeholders (patients, healthcare providers, collection centers, manufacturers, logistics service providers and regulators / payers) involved in the cell and advanced therapies supply chain. It also presents a summary of the diverse needs and areas of concern, along with our opinion (based on past and prevalent trends) on how the industry is preparing to address the aforementioned issues.
Chapter 12 presents a detailed review of the cell and advanced therapies supply chain, offering insights on the processes associated with various stages, such as donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up, along with information on cost requirements and existing opportunities for improvement in the supply chain management practices.
Chapter 13 features an insightful analysis, highlighting the cost saving potential across various processes of the cell and advanced therapies supply chain that can be brought about by the implementation of bespoke and integrated technological solutions / software systems.
Chapter 14 features a comprehensive market forecast, highlighting the future potential of the supply chain management software solutions market till 2030, based on multiple parameters, such as number of cell and advanced therapies in development, expected pricing, likely adoption rates, and cost saving opportunity from different software systems. In addition, we have provided the likely distribution of the current and forecasted opportunity across [A] different software systems (COP, EMS, IMS, LIMS, LMS, PMS, QMS, and TTS), [B] applications (donor eligibility assessment, sample collection, manufacturing, logistics, and patient verification and treatment follow-up), [C] modes of deployment (cloud and on-premises), [D] end users (biobanks, cell therapy labs, hospitals, research institutes, and commercial organizations), and [E] key geographical regions (North America, Europe and Asia-Pacific). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry’s evolution.
Chapter 15 is a collection of executive insights of the discussions that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Bryan Poltilove (Vice President and General Manager, Thermo Fisher Scientific), Jacqueline Barry (Chief Clinical Officer, Cell and Gene Therapy Catapult), Jill Maddux (Director, Cell and Gene Therapy Product Strategy, McKesson) and Divya Iyer (Senior Director, Corporate Strategy and Business Development, McKesson), and Martin Lamb (Chief Business Officer, TrakCel)
Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.
Chapter 17 is an appendix, which provides a comprehensive list of technological solutions / software systems that are being used to effectively manage and streamline the supply chain processes of the overall healthcare industry.
Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Context and Background
3.2. An Introduction to Cell and Advanced Therapies
3.2.1. Classification of Advanced Therapy Medicinal Products
3.2.2. Current Market Landscape
3.3. Cell and Advanced Therapies Supply Chain
3.3.1. Key Processes
3.3.1.1. Donor Eligibility Assessment
3.3.1.2. Sample Collection
3.3.1.3. Manufacturing
3.3.1.4. Logistics
3.3.1.5. Patient Verification and Treatment Follow-up
3.3.2. Challenges Associated with the Cell and Advanced Therapies Supply Chain
3.3.2.1. Process Standardization
3.3.2.2. Process Qualification
3.3.2.3. Chain of Custody Documentation
3.3.2.4. Capacity Scheduling and Resource Utilization
3.3.2.5. Packaging and Shipping Qualification
3.3.2.6. Validation of Storage Containers
3.4. Software Solutions for Cell and Advanced Therapies Supply Chain Management
3.4.1. Cell Orchestration Platform
3.4.2. Enterprise Manufacturing System
3.4.3. Inventory Management System
3.4.4. Laboratory Information Management System
3.4.5. Logistics Management System
3.4.6. Patient Management System
3.4.7. Quality Management System
3.4.8. Tracking and Tracing System
3.5. Growth Drivers and Roadblocks
3.6. Emergence of Digital Technologies in Supply Chain Management
3.6.1. Blockchain Technology
3.6.2. Internet of Things
3.6.3. Augmented Reality
3.6.4. Big Data Analytics
3.6.5. Artificial Intelligence
4. CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Advanced Therapies Supply Chain Management: Overall Market Landscape
4.2.1. Analysis by Type of Software Solution
4.2.2. Analysis by Key Specification and Benefit
4.3.3. Analysis by Application
4.3.4. Analysis by End User
4.3.5. Analysis by Mode of Deployment
4.3.6. Analysis by Scale of Management
4.3.7. Analysis by Regulatory Certifications / Accreditations
4.3. Cell and Advanced Therapies Supply Chain Management: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Location of Headquarters
4.2.3. Analysis by Size of Company
4.3.4. Analysis by Support Services Offered
4.3.5. Leading Developers: Analysis by Number of Software Solutions
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions and Key Parameters
5.4. Competitiveness Analysis: Overview of Supply Chain Management Software Solution Providers
5.4.1. Small-sized Companies
5.4.2. Mid-sized Companies
5.4.3. Large Companies
6. CORE SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Brooks Life Sciences
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. BiobankPro®: Software Description
6.2.4. Recent Developments and Future Outlook
6.3. Cryoport
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Cryoportal®: Software Description
6.3.4. Recent Developments and Future Outlook
6.4. MasterControl
6.4.1. Company Overview
6.4.2. MasterControl Platform™: Software Description
6.4.3. Recent Developments and Future Outlook
6.5. SAP
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. SAP S/4HANA®: Software Description
6.5.4. Recent Development and Future Outlook
6.6. Savsu Technologies
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. evo® Cold Chain 2.0™: Software Description
6.6.4. Recent Development and Future Outlook
6.7. TraceLink
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Digital Supply Chain Platform: Software Description
6.7.4. Recent Developments and Future Outlook
7. CELL ORCHESTRATION PLATFORMS: EMERGING TRENDS AND PROFILES OF KEY PLAYERS
7.1. Chapter Overview
7.2. Supply Chain Orchestration Platforms
7.2.1. Key Functions of Supply Chain Orchestration Platforms
7.2.2. Advantages of Supply Chain Orchestration Platforms
7.2.3. Supply Chain Orchestration Platform Implementation Strategies
7.2.3.1. Building the Required Foundation
7.2.3.2. Incorporating an Appropriate Scheduling System
7.2.3.3. Integration with Core Systems / Processes
7.3. Supply Chain Orchestration Platform: Trends on Twitter
7.3.1. Scope and Methodology
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Popular Keywords
7.4. Key Industry Players
7.4.1. Be The Match BioTherapies®
7.4.1.1. Company Overview
7.4.1.2. Financial Information
7.4.1.3. MatchSource®: Software Description
7.4.1.4. Recent Developments and Future Outlook
7.4.2. Clarkston Consulting
7.4.2.1. Company Overview
7.4.2.2. Cell Therapy Orchestration Platform: Software Description
7.4.2.3. Recent Developments and Future Outlook
7.4.3. Haemonetics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
7.4.3.3. EdgeCell®: Software Description
7.4.3.4. Recent Developments and Future Outlook
7.4.4. Hypertrust Patient Data Care
7.4.4.1. Company Overview
7.4.4.2. Hypertrust X-Chain: Software Description
7.4.4.3. Recent Developments and Future Outlook
7.4.5. Lykan Bioscience
7.4.5.1. Company Overview
7.4.5.2. Unnamed Platform: Software Description
7.4.5.3. Recent Developments and Future Outlook
7.4.6. MAK-SYSTEM
7.4.6.1. Company Overview
7.4.6.2. T.C.S.: Software Description
7.4.6.3. Recent Developments and Future Outlook
7.4.7. sedApta Group
7.4.7.1. Company Overview
7.4.7.2. O.S.A.: Software Description
7.4.7.3. Recent Developments and Future Outlook
7.4.8. Stafa Cellular Therapy
7.4.8.1. Company Overview
7.4.8.2. Stafa Cellular Therapy Lab: Software Description
7.4.8.3. Recent Developments and Future Outlook
7.4.9. Title 21 Health Solutions
7.4.9.1. Company Overview
7.4.9.2. Cell Therapy Software: Software Description
7.4.9.3. Recent Developments and Future Outlook
7.4.10. TrakCel
7.4.10.1. Company Overview
7.4.10.2. Financial Information
7.4.10.3. TrakCel™ Cell Orchestration Platform: Software Description
7.4.10.4. Recent Developments and Future Outlook
7.4.11. Vineti
7.4.11.1. Company Overview
7.4.11.2. Financial Information
7.4.11.3. Personalized Therapy Management Software: Software Description
7.4.11.4. Recent Developments and Future Outlook
8. FUNDING AND INVESTMENT ANALYSIS
8.1. Chapter Overview
8.2. Types of Funding
8.3. Cell and Advanced Therapies Supply Chain Management: Recent Funding Instances
8.3.1. Analysis by Number of Funding Instances
8.3.2. Analysis by Amount Invested
8.3.3. Analysis by Type of Funding
8.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Software Solutions
8.3.5. Most Active Players: Analysis by Amount Invested
8.3.6. Most Active Investors: Analysis by Participation
8.3.7. Geographical Analysis by Amount Invested
8.4. Concluding Remarks
9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Cell and Advanced Therapies Supply Chain Management: Recent Collaborations and Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Partner’s Focus Area
9.3.4. Analysis by Type of Software Solution
9.3.5. Most Active Players: Analysis by Number of Partnerships
9.3.6. Analysis by Regions
9.3.6.1. Most Active Players: Regional Analysis by Number of Partnerships
9.3.6.2. Intercontinental and Intracontinental Agreements
10. PLATFORM UTILIZATION USE CASES
10.1. Chapter Overview
10.2. Cell and Advanced Therapies Supply Chain Management: Recent Platform Utilization Use Cases
10.2.1. Analysis by Year of Utilization
10.2.2. Analysis by User’s Focus Area
10.2.3. Analysis by Type of Software Solution
10.2.4. Most Active Players: Analysis by Number of Utilization Instances
10.2.5. Most Active Players: Regional Analysis by Number of Utilization Instances
11. VALUE CHAIN ANALYSIS
11.1. Chapter Overview
11.2. Cell and Advanced Therapies Value Chain
11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
11.3.1. Donor Eligibility Assessment
11.3.2. Sample Collection
11.3.3. Manufacturing
11.3.4. Logistics
11.3.5. Patient Verification and Treatment Follow-up
12. STAKEHOLDER NEEDS ANALYSIS
12.1. Chapter Overview
12.2. Cell and Advanced Therapies Supply Chain Management: Needs of Different Stakeholders
12.2.1. Comparison of Stakeholder Needs
13. COST SAVINGS ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030
13.3.1. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030
13.3.2. Cost Saving Potential in Sample Collection, 2019-2030
13.3.3. Cost Saving Potential in Manufacturing, 2019-2030
13.3.4. Cost Saving Potential in Logistics, 2019-2030
13.3.5. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Key Assumptions and Forecast Methodology
14.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030
14.3.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application
14.3.1.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.3.1.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.3.1.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.3.1.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.3.1.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
14.3.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User
14.3.2.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030
14.3.2.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030
14.3.2.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030
14.3.2.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030
14.3.2.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030
14.3.3. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution
14.3.3.1. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.2. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.3. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.4. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.5. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.6. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.3.7. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030
14.3.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment
14.3.4.1. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030
14.3.4.2. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030
14.3.5. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography
14.3.5.1. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030
14.3.5.2. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030
14.4. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Type of Software Solution and Mode of Deployment
14.4.1. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030
14.4.1.1.1. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.1.2. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
14.4.1.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030
14.4.1.2.1. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030
14.4.1.2.2. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030
14.4.2. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030
14.4.2.1. Inventory Management Systems Market for Sample Collection, 2019-2030
14.4.2.1.1. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.1.2. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.2. Laboratory Information Management Systems Market for Sample Collection, 2019-2030
14.4.2.2.1. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.2.2. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.3. Logistics Management Systems Market for Sample Collection, 2019-2030
14.4.2.3.1. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.3.2. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.4. Quality Management Systems Market for Sample Collection, 2019-2030
14.4.2.4.1. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.4.2. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.2.5. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030
14.4.2.5.1. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
14.4.2.5.2. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
14.4.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030
14.4.3.1. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030
14.4.3.1.1. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.1.2. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.2. Inventory Management Systems Market for Manufacturing, 2019-2030
14.4.3.2.1. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.2.2. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.3. Laboratory Information Management Systems Market for Manufacturing, 2019-2030
14.4.3.3.1. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.3.2. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.4. Quality Management Systems Market for Manufacturing, 2019-2030
14.4.3.4.1. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.4.2. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.3.5. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030
14.4.3.5.1. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
14.4.3.5.2. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
14.4.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030
14.4.4.1. Logistics Management Systems Market for Logistics, 2019-2030
14.4.4.1.1. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.1.2. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030
14.4.4.2. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030
14.4.4.2.1. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
14.4.4.2.2. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
14.4.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.1.1. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.1.2. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
14.4.5.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030
14.4.5.2.1. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030
14.4.5.2.2. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Thermo Fisher Scientific
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Bryan Poltilove, Vice President and General Manager
15.3. Cell and Gene Therapy Catapult
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Jacqueline Barry, Chief Clinical Officer
15.4. McKesson
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Jill Maddux, Director, Cell and Gene Therapy Product Strategy, and Divya Iyer, Senior Director, Corporate Strategy and Business Development
15.5. TrakCel
15.5.1. Company Snapshot
15.5.2. Interview Transcript: Martin Lamb, Chief Business Officer
16. CONCLUDING REMARKS
16.1. Chapter Overview
16.2. Key Takeaways
17. APPENDIX 1: LIST OF ADDITIONAL SUPPLY CHAIN MANAGEMENT SOFTWARE SOLUTIONS
18. APPENDIX 2: TABULATED DATA
19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1. Classification of Advanced Therapy Medicinal Products
Figure 3.2. Market Access Landscape of Key Cell and Advanced Therapies across Different Geographies
Figure 3.3. Key Processes of Cell and Advanced Therapies Supply Chain
Figure 3.4. Responsibilities of Stakeholders Involved in Cell and Advanced Therapies Supply Chain
Figure 3.4. Key Steps Involved in the Manufacturing of Cell and Advanced Therapies
Figure 3.5. Keys Steps Involved in Logistics Operations of Autologous Therapies
Figure 3.6. Comparison of Logistics Processes for Autologous and Allogeneic Therapies
Figure 3.7. Key Challenges Related to Cell and Advanced Therapies Supply Chain
Figure 3.8. Key Considerations for Transportation of Cell and Advanced Therapies
Figure 3.9. Temperature Variations across Cryogenic Vessels / Dewars for Storage of Cell and Advanced Therapies
Figure 3.10. Recommendations for Process Qualification of Cell and Advanced Therapies
Figure 3.11. Overview of Supply Chain Orchestration Platforms
Figure 3.12. Functions of Key Software Solutions for Cell and Advanced Therapies Supply Chain Management
Figure 3.13. Growth Drivers and Roadblocks to Software Solutions in Cell and Advanced Therapies Supply Chain
Figure 4.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Figure 4.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Figure 4.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Figure 4.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Figure 4.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Figure 4.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Figure 4.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Figure 4.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Figure 4.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Figure 4.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Figure 4.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Figure 4.12. Leading Developers: Distribution by Number of Software Solutions
Figure 5.1. Competitiveness Analysis of Small-sized Supply Chain Management Software Solutions Providers
Figure 5.2. Competitiveness Analysis of Mid-sized Supply Chain Management Software Solutions Providers
Figure 5.3. Competitiveness Analysis of Large-sized Supply Chain Management Software Solutions Providers
Figure 6.1. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.2. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 6.3. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Figure 7.1. Standardization of Tasks by Supply Chain Orchestration Platforms
Figure 7.2. Key Functions of Supply Chain Orchestration Platforms
Figure 7.3. Advantages of Supply Chain Orchestration Platforms
Figure 7.4. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Figure 7.5. Trends on Social Media: Popular Keywords
Figure 7.6. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Figure 8.1. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Figure 8.2. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Figure 8.3. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 8.4. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Figure 8.5. Funding and Investments: Distribution by Type of Funding
Figure 8.6. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Figure 8.7. Popular Software Solutions: Distribution by Number of Funding Instances
Figure 8.8. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Figure 8.9. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Figure 8.10. Most Active Players: Distribution by Number of Instances
Figure 8.11. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Figure 8.12. Most Active Investors: Distribution by Number of Instances
Figure 8.13. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Figure 8.14. Funding and Investment Summary
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Figure 9.4. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Software Solution
Figure 9.6. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Figure 9.7. Most Active Players: Distribution by Number of Partnerships
Figure 9.8. Most Active Players: Regional Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Figure 10.1. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Figure 10.2. Platform Utilization Use Cases: Distribution by User’s Focus Area
Figure 10.3. Platform Utilization Use Cases: Distribution by Type of Software Solution
Figure 10.4. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Figure 10.5. Most Active Players: Distribution by Number of Utilization Instances
Figure 10.6. Most Active Players: Regional Distribution by Number of Utilization Instances
Figure 11.1. Key Processes of Cell and Advanced Therapies Value Chain
Figure 11.2. Cell and Advanced Therapies Value Chain: Cost Distribution
Figure 11.3. Cell and Advanced Therapies Value Chain: Donor Eligibility Assessment
Figure 11.4. Cell and Advanced Therapies Value Chain: Sample Collection
Figure 11.5. Cell and Advanced Therapies Value Chain: Manufacturing
Figure 11.6. Cell and Advanced Therapies Value Chain: Logistics
Figure 11.7. Cell and Advanced Therapies Value Chain: Patient Verification and Treatment Follow-up
Figure 12.1. Cell and Advanced Therapies Supply Chain Management: Stakeholders Needs Analysis
Figure 12.2. Comparison of Stakeholder Needs
Figure 13.1. Overall Cost Saving Potential of Supply Chain Management: Likely Scenarios
Figure 13.2. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Figure 13.3. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 13.4. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Figure 13.5. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Figure 13.6. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Figure 13.7. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.1. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, 2019-2030 (USD Million)
Figure 14.2. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, 2019-2030 (USD Million)
Figure 14.3. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.4. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.5. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.6. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, 2019-2030 (USD Million)
Figure 14.7. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.8. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, 2019-2030 (USD Million)
Figure 14.9. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, 2019-2030 (USD Million)
Figure 14.10. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, 2019-2030 (USD Million)
Figure 14.11. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, 2019-2030 (USD Million)
Figure 14.12. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, 2019-2030 (USD Million)
Figure 14.13. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, 2019-2030 (USD Million)
Figure 14.14. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, 2019-2030 (USD Million)
Figure 14.15. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.16. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.17. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.18. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.19. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.20. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.21. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, 2019-2030 (USD Million)
Figure 14.22. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, 2019-2030 (USD Million)
Figure 14.23. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.24. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, 2019-2030 (USD Million)
Figure 14.25. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 14.26. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, 2019-2030 (USD Million)
Figure 14.27. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, 2019-2030 (USD Million)
Figure 14.28. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, 2019-2030 (USD Million)
Figure 14.29. Patient Management Systems Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.30. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.31. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.32. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, 2019-2030 (USD Million)
Figure 14.33. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.34. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.35. Inventory Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.36. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.37. Inventory Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.38. Laboratory Information Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.39. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.40. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.41. Logistics Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.42. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.43. Logistics Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.44. Quality Management Systems Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.45. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.46. Quality Management Systems Market for Sample Collection: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.47. Supply Chain Orchestration Platforms Market for Sample Collection, 2019-2030 (USD Million)
Figure 14.48. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, 2019-2030
Figure 14.49. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, 2019-2030
Figure 14.50. Enterprise Manufacturing Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.51. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.52. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.53. Inventory Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.54. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.55. Inventory Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.56. Laboratory Information Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.57. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.58. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.59. Quality Management Systems Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.60. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.61. Quality Management Systems Market for Manufacturing: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.62. Supply Chain Orchestration Platforms Market for Manufacturing, 2019-2030 (USD Million)
Figure 14.63. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, 2019-2030
Figure 14.64. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, 2019-2030
Figure 14.65. Logistics Management Systems Market for Logistics, 2019-2030 (USD Million)
Figure 14.66. Logistics Management Systems Market for Logistics: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.67. Logistics Management Systems Market for Logistics: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.68. Supply Chain Orchestration Platforms Market for Logistics, 2019-2030 (USD Million)
Figure 14.69. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, 2019-2030
Figure 14.70. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, 2019-2030
Figure 14.71. Patient Management Systems Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.72. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.73. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)
Figure 14.74. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Figure 14.75. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, 2019-2030 (USD Million)
Figure 14.76. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, 2019-2030 (USD Million)
Table 3.1. Applications of Cell and Advanced Therapies
Table 3.2. Differences between Cell and Advanced Therapies and Biotechnology Products
Table 3.3. Cell and Advanced Therapies: Commercialized Products
Table 4.1. Cell and Advanced Therapies Supply Chain Management: Information on Type of Software Solution
Table 4.2. Cell and Advanced Therapies Supply Chain Management: Information on Key Software Specifications and Benefits
Table 4.3. Cell and Advanced Therapies Supply Chain Management: Information on Key Applications and End Users
Table 4.4. Cell and Advanced Therapies Supply Chain Management: Information on Mode of Deployment, Scale of Management and Key Regulatory Certifications / Accreditations
Table 4.5. Cell and Advanced Therapies Supply Chain Management: Developer Overview
Table 4.6. Cell and Advanced Therapies Supply Chain Management: Information on key Support Services Offered
Table 6.1. Brooks Life Sciences: Key Highlights
Table 6.2. Brooks Life Sciences: Key Characteristics of BiobankPro®
Table 6.3. Brooks Life Sciences: Recent Developments and Future Outlook
Table 6.4. Cryoport: Key Highlights
Table 6.5. Cryoport: Key Characteristics of Cryoportal®
Table 6.6. Cryoport: Recent Developments and Future Outlook
Table 6.7. MasterControl: Key Highlights
Table 6.8. MasterControl: Key Characteristics of MasterControl Platform™
Table 6.9. MasterControl: Recent Developments and Future Outlook
Table 6.10. SAP: Key Highlights
Table 6.11. SAP: Key Characteristics of SAP S/4HANA®
Table 6.12. SAP: Recent Developments and Future Outlook
Table 6.13. Savsu Technologies: Key Highlights
Table 6.14. Savsu Technologies: Funding Instances
Table 6.15. Savsu Technologies: Key Characteristics of evo® Cold Chain 2.0™
Table 6.16. Savsu Technologies: Recent Developments and Future Outlook
Table 6.17. TraceLink: Key Highlights
Table 6.18. TraceLink: Funding Instances
Table 6.19. TraceLink: Key Characteristics of Digital Supply Chain Platform
Table 6.20. TraceLink: Recent Developments and Future Outlook
Table 7.1. Be The Match BioTherapies®: Key Highlights
Table 7.2. Be The Match BioTherapies®: Key Characteristics of MatchSource®
Table 7.3. Be The Match BioTherapies®: Recent Developments and Future Outlook
Table 7.4. Clarkston Consulting: Key Highlights
Table 7.5. Clarkston Consulting: Key Characteristics of Cell Therapy Orchestration Platform
Table 7.6. Clarkston Consulting: Recent Developments and Future Outlook
Table 7.7. Haemonetics: Key Highlights
Table 7.8. Haemonetics: Key Characteristics of EdgeCell®
Table 7.9. Haemonetics: Recent Developments and Future Outlook
Table 7.10. Hypertrust Patient Data Care: Key Highlights
Table 7.11. Hypertrust Patient Data Care: Key Characteristics of Hypertrust X-Chain
Table 7.12. Hypertrust Patient Data Care: Recent Developments and Future Outlook
Table 7.13. Lykan Bioscience: Key Highlights
Table 7.14. Lykan Bioscience: Key Characteristics of Unnamed Cell Orchestration Platform
Table 7.15. Lykan Bioscience: Recent Developments and Future Outlook
Table 7.16. MAK-SYSTEM: Key Highlights
Table 7.17. MAK-SYSTEM: Key Characteristics of T.C.S.
Table 7.18. MAK-SYSTEM: Recent Developments and Future Outlook
Table 7.19. sedApta Group: Key Highlights
Table 7.20. sedApta Group: Key Characteristics of O.S.A.
Table 7.21. sedApta Group: Recent Developments and Future Outlook
Table 7.22. Stafa Cellular Therapy: Key Highlights
Table 7.23. Stafa Cellular Therapy: Key Characteristics of Stafa Cellular Therapy Lab
Table 7.24. Stafa Cellular Therapy: Recent Developments and Future Outlook
Table 7.25. Title 21 Health Solutions: Key Highlights
Table 7.26. Title 21 Health Solutions: Key Characteristics of Cell Therapy Software
Table 7.27. Title 21 Health Solutions: Recent Developments and Future Outlook
Table 7.28. TrakCel: Key Highlights
Table 7.29. TrakCel: Funding Instances
Table 7.20. TrakCel: Key Characteristics of TrakCel™ Cell Orchestration Platform
Table 7.31. TrakCel: Recent Developments and Future Outlook
Table 7.32. Vineti: Key Highlights
Table 7.33. Vineti: Funding Instances
Table 7.34. Vineti: Key Characteristics of Personalized Therapy Management Software
Table 7.35. Vineti: Recent Developments and Future Outlook
Table 8.1. Cell and Advanced Therapies Supply Chain Management: List of Funding Instances, 2014-Q3 2019
Table 8.2. Cell and Advanced Therapies Supply Chain Management: Summary of Investments
Table 9.1. Cell and Advanced Therapies Supply Chain Management: List of Partnerships, 2014-Q3 2019
Table 9.2. Most Active Players: Regional Distribution by Number of Partnerships
Table 10.1. Cell and Advanced Therapies Supply Chain Management: List of Platform Utilization Use Cases, 2014-Q3 2019
Table 15.1. Thermo Fisher Scientific: Key Highlights
Table 15.2. Cell and Gene Therapy Catapult: Key Highlights
Table 15.3. McKesson: Key Highlights
Table 15.4. TrakCel: Key Highlights
Table 16.1. Cell and Advanced Therapies Supply Chain Management: Key Takeaways of the Report
Table 17.1. List of Additional Supply Chain Management Software Solutions
Table 19.1. Cell and Advanced Therapies Supply Chain Management: Distribution by Type of Software Solution
Table 19.2. Cell and Advanced Therapies Supply Chain Management: Distribution by Key Specifications and Benefits
Table 19.3. Cell and Advanced Therapies Supply Chain Management: Distribution by Application
Table 19.4. Cell and Advanced Therapies Supply Chain Management: Distribution by End User
Table 19.5. Cell and Advanced Therapies Supply Chain Management: Distribution by Mode of Deployment
Table 19.6. Cell and Advanced Therapies Supply Chain Management: Distribution by Scale of Management
Table 19.7. Cell and Advanced Therapies Supply Chain Management: Distribution by Regulatory Certification / Accreditation
Table 19.8. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Year of Establishment
Table 19.9. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Geographical Location
Table 19.10. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Company Size
Table 19.11. Cell and Advanced Therapies Supply Chain Management: Distribution of Industry Players by Services Offered
Table 19.12. Leading Developers: Distribution by Number of Software Solutions
Table 19.13. Brooks Life Sciences: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.14. Cryoport: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.15. SAP: Net Sales, FY 2014 – H1 2019 (USD Million)
Table 19.16. Trends on Social Media: Historical Activity on Twitter, 2015-2018
Table 19.17. Be The Match BioTherapies®: Net Sales, FY 2013 – FY 2018 (USD Billion)
Table 19.18. Funding and Investments: Distribution of Companies by Year of Establishment and Type of Funding, 2014-Q3 2019
Table 19.19. Funding and Investments: Distribution of Amount Invested by Focus Area and Type of Funding, 2014-Q3 2019
Table 19.20. Funding and Investments: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.21. Funding and Investments: Cumulative Amount Invested by Year, 2014-Q3 2019 (USD Million)
Table 19.22. Funding and Investments: Distribution by Type of Funding
Table 19.23. Funding and Investments: Distribution by Amount Invested and Type of Funding (USD Million)
Table 19.24. Popular Software Solutions: Distribution by Number of Funding Instances
Table 19.25. Popular Software Solutions: Distribution by Amount Invested (USD Million)
Table 19.26. Funding Instances: Year-wise Trend of Amount Invested across Different Software Solutions, 2014-Q3 2019 (USD Million)
Table 19.27. Most Active Players: Distribution by Number of Instances
Table 19.28. Most Active Players: Distribution by Capital Amount Raised (USD Million)
Table 19.29. Most Active Investors: Distribution by Number of Instances
Table 19.30. Funding and Investments: Geographical Distribution by Amount Invested (USD Million)
Table 19.31. Partnerships and Collaborations: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.32. Partnerships and Collaborations: Distribution by Type of Partnership
Table 19.33. Partnerships and Collaborations: Year-wise Trend by Type of Partnership
Table 19.34. Partnerships and Collaborations: Distribution by Partner’s Focus Area
Table 19.35. Partnerships and Collaborations: Distribution by Type of Software Solution
Table 19.36. Partnerships and Collaborations: Year-wise Trend by Type of Software Solution
Table 19.37. Most Active Players: Distribution by Number of Partnerships
Table 19.38. Most Active Players: Regional Distribution by Number of Partnerships
Table 19.39. Partnerships and Collaborations: Regional Distribution (Intercontinental and Intracontinental Agreements)
Table 19.40. Platform Utilization Use Cases: Cumulative Year-wise Trend, 2014-Q3 2019
Table 19.41. Platform Utilization Use Cases: Distribution by User’s Focus Area
Table 19.42. Platform Utilization Use Cases: Distribution by Type of Software Solution
Table 19.43. Platform Utilization Use Cases: Year-wise Trend by Type of Software Solution
Table 19.44. Most Active Players: Distribution by Number of Utilization Instances
Table 19.45. Most Active Players: Regional Distribution by Number of Utilization Instances
Table 19.46. Cell and Advanced Therapies Value Chain: Cost Distribution
Table 19.47. Overall Cost Saving Potential of Supply Chain Management Software Solutions, 2019-2030 (USD Million)
Table 19.48. Cost Saving Potential in Donor Eligibility Assessment, 2019-2030 (USD Million)
Table 19.49. Cost Saving Potential in Sample Collection, 2019-2030 (USD Million)
Table 19.50. Cost Saving Potential in Manufacturing, 2019-2030 (USD Million)
Table 19.51. Cost Saving Potential in Logistics, 2019-2030 (USD Million)
Table 19.52. Cost Saving Potential in Patient Verification and Treatment Follow-up, 2019-2030 (USD Million)
Table 19.53. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Conservative Scenario, 2019-2030 (USD Million)
Table 19.54. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Base Scenario, 2019-2030 (USD Million)
Table 19.55. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.56. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Conservative Scenario, 2019-2030 (USD Million)
Table 19.57. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Base Scenario, 2019-2030 (USD Million)
Table 19.58. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Application, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.59. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.60. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.61. Cell and Advanced Therapies Supply Chain Management Solutions Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.62. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.63. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.64. Cell and Advanced Therapies Supply Chain Management Solutions Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.65. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.66. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.67. Cell and Advanced Therapies Supply Chain Management Solutions Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.68. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.69. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.70. Cell and Advanced Therapies Supply Chain Management Solutions Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.71. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.72. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.73. Cell and Advanced Therapies Supply Chain Management Solutions Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.74. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Conservative Scenario, 2019-2030 (USD Million)
Table 19.75. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Base Scenario, 2019-2030 (USD Million)
Table 19.76. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by End User, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.77. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Conservative Scenario, 2019-2030 (USD Million)
Table 19.78. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Base Scenario, 2019-2030 (USD Million)
Table 19.79. Cell and Advanced Therapies Supply Chain Management Solutions Market for Biobanks, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.80. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Conservative Scenario, 2019-2030 (USD Million)
Table 19.81. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Base Scenario, 2019-2030 (USD Million)
Table 19.82. Cell and Advanced Therapies Supply Chain Management Solutions Market for Cell Therapy Labs, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.83. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Conservative Scenario, 2019-2030 (USD Million)
Table 19.84. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Base Scenario, 2019-2030 (USD Million)
Table 19.85. Cell and Advanced Therapies Supply Chain Management Solutions Market for Hospitals, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.86. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Conservative Scenario, 2019-2030 (USD Million)
Table 19.87. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Base Scenario, 2019-2030 (USD Million)
Table 19.88. Cell and Advanced Therapies Supply Chain Management Solutions Market for Research Institutes, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.89. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Conservative Scenario, 2019-2030 (USD Million)
Table 19.90. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Base Scenario, 2019-2030 (USD Million)
Table 19.91. Cell and Advanced Therapies Supply Chain Management Solutions Market for Commercial Organizations, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.92. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Conservative Scenario, 2019-2030 (USD Million)
Table 19.93. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Base Scenario, 2019-2030 (USD Million)
Table 19.94. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Type of Software Solution, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.95. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.96. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.97. Cell Orchestration Platforms Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.98. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.99. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.100. Enterprise Manufacturing Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.101. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.102. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.103. Inventory Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.104. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.105. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.106. Laboratory Information Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.107. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.108. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.109. Logistics Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.110. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.111. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.112. Patient Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.113. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Conservative Scenario, 2019-2030 (USD Million)
Table 19.114. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Base Scenario, 2019-2030 (USD Million)
Table 19.115. Quality Management Systems Market for Cell and Advanced Therapies Supply Chain Management, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.116. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.117. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Base Scenario, 2019-2030 (USD Million)
Table 19.118. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Mode of Deployment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.119. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.120. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.121. Cell and Advanced Therapies Supply Chain Management Market for Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.122. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.123. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.124. Cell and Advanced Therapies Supply Chain Management Market for On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.125. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 19.126. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 19.127. Overall Cell and Advanced Therapies Supply Chain Management Solutions Market: Distribution by Geography, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.128. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Conservative Scenario, 2019-2030 (USD Million)
Table 19.129. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Base Scenario, 2019-2030 (USD Million)
Table 19.130. Cell and Advanced Therapies Supply Chain Management Solutions Market in North America, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.131. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Conservative Scenario, 2019-2030 (USD Million)
Table 19.132. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Base Scenario, 2019-2030 (USD Million)
Table 19.133. Cell and Advanced Therapies Supply Chain Management Solutions Market in Europe, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.134. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Conservative Scenario, 2019-2030 (USD Million)
Table 19.135. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Base Scenario, 2019-2030 (USD Million)
Table 19.136. Cell and Advanced Therapies Supply Chain Management Solutions Market in Asia-Pacific, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.137. Patient Management Systems Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.138. Patient Management Systems Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.139. Patient Management Systems Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.140. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.141. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.142. Patient Management Systems Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.143. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.144. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.145. Patient Management Systems Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.146. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Conservative Scenario, 2019-2030 (USD Million)
Table 19.147. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Base Scenario, 2019-2030 (USD Million)
Table 19.148. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.149. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.150. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.151. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.152. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.153. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.154. Supply Chain Orchestration Platforms Market for Donor Eligibility Assessment: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.155. Inventory Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.156. Inventory Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.157. Inventory Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.158. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.159. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.160. Inventory Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.161. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.162. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.163. Inventory Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.164. Laboratory Information Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.165. Laboratory Information Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.166. Laboratory Information Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.167. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.168. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.170. Laboratory Information Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.171. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.172. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.173. Laboratory Information Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.174. Logistics Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.175. Logistics Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.176. Logistics Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.177. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.178. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.179. Logistics Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.180. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.181. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.182. Logistics Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.183. Quality Management Systems Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.184. Quality Management Systems Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.185. Quality Management Systems Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.186. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.187. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.188. Quality Management Systems Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.189. Quality Management Systems Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.190. Quality Management Systems Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.191. Quality Management Systems Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.192. Supply Chain Orchestration Platforms Market for Sample Collection, Conservative Scenario, 2019-2030 (USD Million)
Table 19.193. Supply Chain Orchestration Platforms Market for Sample Collection, Base Scenario, 2019-2030 (USD Million)
Table 19.194. Supply Chain Orchestration Platforms Market for Sample Collection, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.195. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.196. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.197. Supply Chain Orchestration Platforms Market for Sample Collection: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.198. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.199. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.200. Supply Chain Orchestration Platforms Market for Sample Collection: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.201. Enterprise Manufacturing Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.202. Enterprise Manufacturing Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.203. Enterprise Manufacturing Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 204. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 205. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 206. Enterprise Manufacturing Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19. 207. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19. 208. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19. 209. Enterprise Manufacturing Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.210. Inventory Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.211. Inventory Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.212. Inventory Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.213. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.214. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.215. Inventory Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.216. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.217. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.218. Inventory Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.219. Laboratory Information Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.220. Laboratory Information Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.221. Laboratory Information Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.222. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.223. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.224. Laboratory Information Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.225. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.226. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.227. Laboratory Information Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.228. Quality Management Systems Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.229. Quality Management Systems Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.230. Quality Management Systems Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.231. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.232. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.233. Quality Management Systems Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.234. Quality Management Systems Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.235. Quality Management Systems Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.236. Quality Management Systems Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.237. Supply Chain Orchestration Platforms Market for Manufacturing, Conservative Scenario, 2019-2030 (USD Million)
Table 19.238. Supply Chain Orchestration Platforms Market for Manufacturing, Base Scenario, 2019-2030 (USD Million)
Table 19.239. Supply Chain Orchestration Platforms Market for Manufacturing, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.240. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.241. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.242. Supply Chain Orchestration Platforms Market for Manufacturing: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.243. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.244. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.245. Supply Chain Orchestration Platforms Market for Manufacturing: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.246. Logistics Management Systems Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.247. Logistics Management Systems Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.248. Logistics Management Systems Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.249. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.250. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.251. Logistics Management Systems Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.252. Logistics Management Systems Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.253. Logistics Management Systems Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.254. Logistics Management Systems Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.255. Supply Chain Orchestration Platforms Market for Logistics, Conservative Scenario, 2019-2030 (USD Million)
Table 19.256. Supply Chain Orchestration Platforms Market for Logistics, Base Scenario, 2019-2030 (USD Million)
Table 19.257. Supply Chain Orchestration Platforms Market for Logistics, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.258. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.259. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.260. Supply Chain Orchestration Platforms Market for Logistics: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.261. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.262. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.263. Supply Chain Orchestration Platforms Market for Logistics: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.264. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.265. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.266. Patient Management Systems Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.267. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.268. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.269. Patient Management Systems Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.270. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.271. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.272. Patient Management Systems Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.273. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Conservative Scenario, 2019-2030 (USD Million)
Table 19.274. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Base Scenario, 2019-2030 (USD Million)
Table 19.275. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.276. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.277. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.278. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: Cloud-based Solutions, Optimistic Scenario, 2019-2030 (USD Million)
Table 19.279. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Conservative Scenario, 2019-2030 (USD Million)
Table 19.280. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Base Scenario, 2019-2030 (USD Million)
Table 19.281. Supply Chain Orchestration Platforms Market for Patient Verification and Treatment Follow-up: On-premises Solutions, Optimistic Scenario, 2019-2030 (USD Million)
The following companies / institutes / government bodies and organizations have been mentioned in this report.
PRICING DETAILS
Discounts available for multiple report purchases
sales@rootsanalysis.com
SUBSCRIBE TO INDUSTRY UPDATES